-
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCIDMF Claassens, GJA Vos, TO Bergmeijer et al. -
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesLevine GN, Bates ER, Bittl JA et al.
-
Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI StudyNL Pereira, CS Rihal, DYF So et al.
-
Prasugrel versus clopidogrel in patients with acute coronary syndromesWiviott SD, Braunwald E, TRITON-TIMI 38 Investigators.
-
Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled TrialK Kanenawa, K Yamaji, H Tashiro et al.
-
Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT SubstudyLee BK, Kim JS, Lee OH et al.
-
Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trialColombo A, Chieffo A, Frasheri A et al.
-
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical TrialHong SJ, Shin DH, IVUS-XPL Investigators.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
